The latest tariff announcement by U.S. President Donald Trump has raised concerns across global markets, with duties on certain patented and branded medicines being raised up to 100 percent. While the move is seen as a sharp escalation in trade measures, industry experts and government officials have stated that India’s pharmaceutical sector is unlikely to be severely affected.

India remains the world’s largest supplier of generic medicines, accounting for nearly 40 percent of all generics consumed in the U.S. Since the new tariff regime primarily targets branded and patented drugs, the bulk of India’s pharmaceutical exports, which are dominated by generics, are expected to remain outside its scope. Analysts suggest this gives India a measure of protection compared to other exporting nations.

A senior official from the Ministry of Commerce & Industry noted, “We are closely monitoring the development. Based on the current structure of the tariff, the impact on India’s pharmaceutical industry will be minimal. India’s core strength lies in supplying affordable generics, which continue to be in high demand in the U.S. healthcare system.”

Industry leaders have also expressed confidence that India’s pharma exports will remain resilient. [Insert Name], President of the Indian Pharmaceutical Alliance (IPA), said, “Indian companies have long been partners in delivering affordable and high-quality generics to the U.S. market. While trade uncertainties do create short-term challenges, our commitment to patients and global healthcare will not waver.”

Looking Ahead

The Government of India has reaffirmed its commitment to engage in constructive dialogue with U.S. counterparts to ensure continuity in trade relations. At the same time, policymakers are exploring opportunities to diversify export markets and strengthen domestic R&D capabilities to reduce exposure to external shocks.

Valued at over USD 50 billion, the Indian pharmaceutical industry has established itself as a global leader in generics and vaccines, exporting to more than 200 countries. With robust manufacturing standards, a growing innovation pipeline, and consistent global demand, the sector is expected to remain a key contributor to both India’s economy and global public health.